Adjuvant Chemotherapy for HER2-Negative Early-Stage Breast Cancer

Breast Cancer ◽  
2018 ◽  
pp. 357-381
Author(s):  
Leyla Ozer ◽  
Adnan Aydiner
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Early Stage ◽  
Early Stage Breast Cancer

Abstract PS13-40: Real-world outcomes in patients receiving neo-adjuvant chemotherapy for early-stage breast cancer

2021 ◽  
Author(s):  
Catherine McDonald ◽  
Rebecca Squires ◽  
Mark Gormley ◽  
Ryan Langdon ◽  
Ann Archer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Real World ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Neo Adjuvant Chemotherapy

scholarly journals Can Chemotherapy-Related Acute Care Visits Be Accurately Identified in Administrative Data?

2018 ◽  
Vol 14 (1) ◽  
pp. e51-e58 ◽  
Author(s):  
Monika K. Krzyzanowska ◽  
Katherine Enright ◽  
Rahim Moineddin ◽  
Lingsong Yun ◽  
Melanie Powis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Emergency Department ◽  
Adjuvant Chemotherapy ◽  
Acute Care ◽  
Administrative Data ◽  
Validation Cohort ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Algorithm Validation ◽  
Ed Visits

Purpose: There is increasing interest in using administrative data to examine treatment-related complications that lead to emergency department (ED) visits or hospitalizations (H). The purpose of this study was to evaluate the reliability of billing codes for identifying chemotherapy-related acute care visits (CRVs) among women with early-stage breast cancer. Materials and Methods: The cohort was identified by using deterministically linked health databases and consisted of women who were diagnosed with early-stage breast cancer who started adjuvant chemotherapy between 2007 and 2009 in Ontario, Canada. A random sample of 496 patient cases was chosen as the validation cohort. Sensitivity (SN) and specificity (SP) were calculated for three scenarios: chemotherapy-related ED visit, chemotherapy-related H, and febrile neutropenia (FN)–related visit. For FN-related visits, three definitions were considered: general, moderate, and strict. Results: The administrative cohort consisted of 8,359 patients, 43.4% of whom had at least one ED or H, including 1,496 women who had multiple visits that resulted in 6,293 unique visits. Of these, 73.1% were considered CRVs. The algorithm performed well in identifying CRVs that included H either from ED (SN, 90%; SP, 100%) or directly from home (SN, 91%; SP, 93%), but less well for ED visits that did not result in H (SN, 65%; SP, 80%). Depending on which FN algorithm was used, 4.8% to 24% of visits were considered related. The moderate FN algorithm provided the best tradeoff between SN (69% to 97%) and SP (83% to 98%). Conclusion: Administrative data can be valuable in evaluating chemotherapy-related serious events. Algorithm validation in other cohorts is needed.

Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer

2012 ◽  
Vol 30 (2) ◽  
pp. 103-118 ◽  
Author(s):  
Robert I. Griffiths ◽  
Richard L. Barron ◽  
Michelle L. Gleeson ◽  
Mark D. Danese ◽  
Anthony OʼHagan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Older Patients ◽  
Early Stage ◽  
Medical Costs ◽  
Early Stage Breast Cancer ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor
Sign in / Sign up

Export Citation Format

Share Document